Ocular Therapeutix Inc
NASDAQ:OCUL

Watchlist Manager
Ocular Therapeutix Inc Logo
Ocular Therapeutix Inc
NASDAQ:OCUL
Watchlist
Price: 7.71 USD -2.41% Market Closed
Market Cap: 1.2B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one OCUL stock under the Base Case scenario is 3.58 USD. Compared to the current market price of 7.71 USD, Ocular Therapeutix Inc is Overvalued by 54%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

OCUL Relative Value
Base Case
3.58 USD
Overvaluation 54%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

19.1
P/S
P/S
Price to Sales
19.1
vs History
44
vs Industry
9
Median 3Y
9.1
Median 5Y
17
Industry
2.4
Forward
16.8
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-6.6
Median 5Y
-6.7
Industry
20.6
Forward
-6.2
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-7.3
Median 5Y
-7.9
Industry
15.5
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-7.2
Median 5Y
-7.7
Industry
23
More Details
3.9
P/B
P/B
Price to Book Value
3.9
vs History
69
vs Industry
19
Median 3Y
5
Median 5Y
6.1
Industry
1.9
More Details
14
EV/S
EV/S
Enterprise Value to Sales
14
vs History
42
vs Industry
10
Median 3Y
7.2
Median 5Y
11.1
Industry
2.5
Forward
12.4
More Details
15.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
15.4
vs History
42
vs Industry
14
Median 3Y
7.9
Median 5Y
12.2
Industry
4.9
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-4.7
Median 5Y
-5.3
Industry
12.6
Forward
-4.7
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-4.6
Median 5Y
-5.2
Industry
15.7
Forward
-4.4
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-5.6
Median 5Y
-6.4
Industry
14
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-5.2
Median 5Y
-6.3
Industry
17.7
More Details
14.5
EV/IC
EV/IC
Enterprise Value to IC
14.5
vs History
39
vs Industry
6
Median 3Y
8.7
Median 5Y
11.7
Industry
1.8
More Details

Multiples Across Competitors

OCUL Competitors Multiples
Ocular Therapeutix Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Ocular Therapeutix Inc
NASDAQ:OCUL
1.2B USD 19.1 -6.3 -5.3 -5.2
US
Eli Lilly and Co
NYSE:LLY
838.1B USD 18.6 79.1 45.9 50.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.1B USD 4.2 17.1 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 6.2 17.7 11.7 13.4
CH
Roche Holding AG
SIX:ROG
208.3B CHF 3.4 25.2 9.5 11.1
CH
Novartis AG
SIX:NOVN
187.4B CHF 4.4 19 11.5 14.7
UK
AstraZeneca PLC
LSE:AZN
161.3B GBP 4 30.5 126.2 192.7
US
Merck & Co Inc
NYSE:MRK
209.1B USD 3.3 12 8.6 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
115.8B EUR 1.3 9.1 5 5.9
P/E Multiple
Earnings Growth PEG
US
Ocular Therapeutix Inc
NASDAQ:OCUL
Average P/E: 26.2
Negative Multiple: -6.3 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
79.1
49%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
17.7
18%
1
CH
Roche Holding AG
SIX:ROG
25.2
32%
0.8
CH
Novartis AG
SIX:NOVN
19
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
30.5
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.1
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Ocular Therapeutix Inc
NASDAQ:OCUL
Average EV/EBITDA: 433.8
Negative Multiple: -5.3 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
45.9
31%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
11.7
14%
0.8
CH
Roche Holding AG
SIX:ROG
9.5
6%
1.6
CH
Novartis AG
SIX:NOVN
11.5
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
126.2
9%
14
US
Merck & Co Inc
NYSE:MRK
8.6
9%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5
8%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Ocular Therapeutix Inc
NASDAQ:OCUL
Average EV/EBIT: 1 867.3
Negative Multiple: -5.2 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
50.7
33%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
16%
0.8
CH
Roche Holding AG
SIX:ROG
11.1
8%
1.4
CH
Novartis AG
SIX:NOVN
14.7
8%
1.8
UK
AstraZeneca PLC
LSE:AZN
192.7
21%
9.2
US
Merck & Co Inc
NYSE:MRK
10.3
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4

See Also

Summary
OCUL intrinsic value, competitors valuation, and company profile.
DCF Valuation
OCUL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
OCUL stock valuation using valuation multiples.
Wall Street Estimates
OCUL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
OCUL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 250,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.